269 related articles for article (PubMed ID: 12351510)
1. HbA(1c) and glycemic profile, basal- and post-treatment with Miglitol, in an area with a Mediterranean diet.
Faure E; Pallardo LF; Mesa J; Puig-Domingo M; García-Mayor R; Benito P; Ravella R; Artés M; López JS;
Diabetes Care; 2002 Oct; 25(10):1896-8. PubMed ID: 12351510
[No Abstract] [Full Text] [Related]
2. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
Chiasson JL; Naditch L;
Diabetes Care; 2001 Jun; 24(6):989-94. PubMed ID: 11375358
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
[TBL] [Abstract][Full Text] [Related]
4. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients.
Pagano G; Marena S; Corgiat-Mansin L; Cravero F; Giorda C; Bozza M; Rossi CM
Diabete Metab; 1995 Jun; 21(3):162-7. PubMed ID: 7556806
[TBL] [Abstract][Full Text] [Related]
5. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
6. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics.
Standl E; Schernthaner G; Rybka J; Hanefeld M; Raptis SA; Naditch L
Diabetes Res Clin Pract; 2001 Mar; 51(3):205-13. PubMed ID: 11269893
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
[TBL] [Abstract][Full Text] [Related]
8. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Scott LJ; Spencer CM
Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
[TBL] [Abstract][Full Text] [Related]
9. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
Holman RR; Steemson J; Turner RC
Diabetes Res; 1991 Dec; 18(4):149-53. PubMed ID: 1842749
[TBL] [Abstract][Full Text] [Related]
10. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
[TBL] [Abstract][Full Text] [Related]
11. [Risk of complications in the diabetic patient. Postprandial blood glucose peaks as deciding factor].
MMW Fortschr Med; 2000 Jul; 142(26-27):54-5. PubMed ID: 10929491
[No Abstract] [Full Text] [Related]
12. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
13. Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
Van Gaal L; Maislos M; Schernthaner G; Rybka J; Segal P
Diabetes Obes Metab; 2001 Oct; 3(5):326-31. PubMed ID: 11703422
[TBL] [Abstract][Full Text] [Related]
14. [Miglitol in the treatment of the insulin-dependent diabetic patient. Improved metabolic control and excellent tolerance].
Rinninger F; Lotz N; Hillebrand I; Bachmann W
Fortschr Med; 1987 Jul; 105(22):435-8. PubMed ID: 3653827
[No Abstract] [Full Text] [Related]
15. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
[TBL] [Abstract][Full Text] [Related]
16. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A
Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
[TBL] [Abstract][Full Text] [Related]
17. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
[TBL] [Abstract][Full Text] [Related]
19. Miglitol for type 2 diabetes mellitus.
Med Lett Drugs Ther; 1999 May; 41(1053):49-50. PubMed ID: 10368700
[No Abstract] [Full Text] [Related]
20. [Drug therapy of type 2 diabetes: insulin sensitizers improve results].
Stadler HJ
Pflege Z; 1999 Nov; 52(11):772-5. PubMed ID: 10788929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
